Navigation Links
Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
Date:5/26/2012

oking information and statements. These risks and uncertainties include among other things, the uncertainties inherent in research and development, future clinical data and analysis, including post marketing, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug, device or biological application that may be filed for any such product candidates as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, the absence of guarantee that the product candidates if approved will be commercially successful, the future approval and commercial success of therapeutic alternatives, the Group's ability to benefit from external growth opportunities, trends in exchange rates and prevailing interest rates, the impact of cost containment policies and subsequent changes thereto, the average number of shares outstanding as well as those discussed or identified in the public filings with the SEC and the AMF made by Sanofi, including those listed under "Risk Factors" and "Cautionary Statement Regarding Forward-Looking Statements" in Sanofi's annual report on Form 20-F for the year ended December 31, 2011. Other than as required by applicable law, Sanofi does not undertake any obligation to update or revise any forward-looking information or statements.

Regeneron Forward-Looking Statements

This news release includes forward-looking statements that involve risks and uncertainties relating to future events and the future performance of Regeneron, and actual events or results may differ materially from these forward-looking statements. These statements concern, and these risks and uncertainties include, among others, the nature, timing, and possible success and therapeutic applications of Regeneron's product candidates and research and clinical programs now underway or planned, including without limitation SAR236553/REGN727, unfo
'/>"/>

SOURCE Sanofi and Regeneron Pharmaceuticals, Inc
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Sanofi Aventis : New Study Results Support the "Basal Plus" Strategy With LANTUS(R) and APIDRA(R) to Improve Blood Sugar Control in Patients With Type 2 Diabetes
2. RainDance Technologies Signs a Collaboration Agreement with sanofi-aventis and Louis Pasteur University to Launch dScreen Consortium within ALSACE BIOVALLEY cluster
3. Russia Chooses Inactivated Polio Vaccine from Sanofi Pasteur for Primary Immunization of all Infants
4. AEterna Zentaris and Sanofi-Aventis Sign a Development, Commercialization and Licensing Agreement for Cetrorelix in Benign Prostatic Hyperplasia
5. BioWa Announces License of POTELLIGENT(R) Technology to sanofi-aventis
6. Sanofi-aventis U.S. to Acquire Oral Chronic Lymphocytic Leukemia Treatment
7. Sanofi Pasteur Receives Seed Virus to Produce New Influenza A(H1N1) Vaccine
8. Sanofi-aventis U.S. Announces Settlement of Medicaid Best Price Investigation
9. Sanofi Pasteur Responds to Nations Need for Hib Vaccine With Increased Supply
10. Sanofi-aventis Announces Second Quarter 2009 Results
11. Sanofi-aventis U.S. Introduces BenzaClin(R) Carekit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... August 27, 2014 Flagship Biosciences LLC, ... services to the pharmaceutical and medical device industries, has ... The fast growing company has consolidated its histology and ... Boulder to Westminster, CO, just north of Denver. ... 7575 W. 103rd Ave., Suite 100, Westminster, CO 80021 ...
(Date:8/27/2014)... , Aug. 27, 2014 Research and ... "Global Enzyme for Pulp & Paper Industry Report 2014" ... Global Enzyme for Pulp & Paper Industry Report 2014 ... state of the global enzyme for pulp & paper ... of the industry including definitions, classifications, applications and industry ...
(Date:8/27/2014)... Aug. 27, 2014 Research and Markets ... Isotope Ratio Mass Spectrometer Industry Report 2014" report ... Isotope Ratio Mass Spectrometer Industry Report 2014 is a ... the global isotope ratio mass spectrometer industry. ... including definitions, classifications, applications and industry chain structure. The ...
(Date:8/27/2014)... -- ARCH Venture Partners, one of the largest U.S. ... seed and early-stage advanced technology companies, today announced ... than $400 million in subscriptions. ARCH Venture Fund ... more than $150 million. "The enthusiasm ... of our approach to finding and funding new ...
Breaking Biology Technology:Flagship Biosciences Announces Relocation and Expansion 2Global Enzyme for Pulp & Paper Industry Report 2014 2Global Stable Isotope Ratio Mass Spectrometer Industry Report 2014 2Latest ARCH Venture Partners Fund Closes Above $400 Million 2Latest ARCH Venture Partners Fund Closes Above $400 Million 3
... the Board ... Neill Named President, ISELIN, N.J., Jan. 3 Pharmos Corporation,(Nasdaq: ... effective immediately., Board Changes, Robert F. Johnston has been elected ... and Mony Ben Dor have retired from,the Board., The Pharmos Board ...
... Jan. 3 Cambrex,Corporation (NYSE: CBM ) ... President and Chief Executive Officer, will make a ... on January 8, 2008 at,9:00 a.m. PST at ... (Logo: http://www.newscom.com/cgi-bin/prnh/20000613/CAMBREXLOGO ), A live ...
... Manufacture; Genzyme will Continue to Market and ... ... CAMBRIDGE, Mass., Jan. 3 ,BioMarin Pharmaceutical Inc. (Nasdaq and SWX: ... restructuring of their joint venture,regarding Aldurazyme(R) (laronidase). Under the revised ...
Cached Biology Technology:Pharmos Corporation Announces Board and Management Changes 2Pharmos Corporation Announces Board and Management Changes 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 2BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 3BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 4BioMarin and Genzyme Restructure Aldurazyme 50/50 Joint Venture 5
(Date:8/27/2014)... North Carolina State University have found that century-old museum specimens ... common insect pest that can weaken and kill trees ... that scale insect populations increase on oak and maple trees ... pests may also increase with global warming," says Dr. Elsa ... of a paper on the work. , "More scale insects ...
(Date:8/26/2014)... University in St. Louis have developed algorithms to identify ... tearing or breaking. The technology, which needs to be ... may help pinpoint minor strains and tiny injuries in ... The research is available online Aug. 27 in the ... publishes research at the nexus of the physical and ...
(Date:8/26/2014)... colony of harmful bacteria, biofilms make the treatment ... a biofilm pose a significant health risk due ... and biofilm-protected bacteria account for some 80 percent ... 50 to 1,000 times more resistant to antibiotics ... may have stumbled onto a magic bullet," said ...
Breaking Biology News(10 mins):Museum specimens, modern cities show how an insect pest will respond to climate change 2New technology may identify tiny strains in body tissues before injuries occur 2New technology may identify tiny strains in body tissues before injuries occur 3Breakthrough antibacterial approach could resolve serious skin infections 2Breakthrough antibacterial approach could resolve serious skin infections 3
... system, every protein made in the cell has a specific ... proteins to their appropriate target. Researchers at Boston University ... images of these channels as they open to allow proteins ... made. These findings are published as a Letter in ...
... apps, cameras, and mobile internet to navigate strange cities in ... in line, and upload their videos directly to social media ... high-tech savvy can save a well-loved device from dying when ... same basic ailment that plagues solar power plants and wind ...
... A drug currently on the market to treat leukemia reversed ... findings by medical researchers with the University of Alberta. ... team,s discovery in the peer-reviewed journal, PLOS ONE . ... can also play an important role in the development of ...
Cached Biology News:Researchers capture images of open channel that moves proteins across cell membranes 2Futuristic copper foam batteries get more bang for the buck 2Futuristic copper foam batteries get more bang for the buck 3UAlberta medical researchers discover potential new treatment for colitis 2UAlberta medical researchers discover potential new treatment for colitis 3
Biotin-OSu is used to label proteins, immunological agents, DNA and synthetic oligonucleotides. Biotin labeling is detected through enzymatically labeled avidin or streptavidin proteins that conforma...
EGTA, 10 g. Ethylene glycol-O,O-bis-[2-amino-ethyl]-N,N,N,N,-tetraacetic acid.Assay: > 99.0%. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
GOAT ANTI FRK...
UV LAMP 300 NM 8W T5, 1 EA. Category: Nucleid Acid Detection Systems....
Biology Products: